---
title: "China Approves Registration for King-Friend Biochemical Pharma Unit's Breast Cancer Injection"
date: "2025-02-11 16:50:43"
summary: "China's medical products administrator approved Nanjing King-Friend Biochemical Pharmaceutical's drug registration for its fulvestrant injection for breast cancer, according to a Tuesday filing with the Shanghai Stock Exchange. The drug is indicated for post-menopausal estrogen-receptor-positive locally advanced or metastatic breast cancer that relapses following or during anti-estrogen adjuvant therapy, the..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

China's medical products administrator approved Nanjing King-Friend Biochemical Pharmaceutical's drug registration for its fulvestrant injection for breast cancer, according to a Tuesday filing with the Shanghai Stock Exchange.

The drug is indicated for post-menopausal estrogen-receptor-positive locally advanced or metastatic breast cancer that relapses following or during anti-estrogen adjuvant therapy, the filing said.

The injection is used simultaneously with abemaciclib for hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer, among other types, the filing said.

Shares closed 2% higher during Tuesday's afternoon trading.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250211:G2466207:0/)
